DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) - Trial NCT06276283
Access comprehensive clinical trial information for NCT06276283 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dizal Pharmaceuticals and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dizal Pharmaceuticals
Timeline & Enrollment
Phase 2
Feb 15, 2023
Feb 28, 2026
Primary Outcome
Part A: 1) Dose Limiting Toxicity (DLT); 2) Treatment-Emergent Adverse Events (TEAEs); TEAEs ≥CTCAE grade 3; and Serious Adverse Events (SAEs). Part B: 1) TEAEs; TEAEs ≥CTCAE grade 3; and SAEs.
Summary
This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with
 advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care,
 which aims to understand whether the combination therapy is safe, how well the combination
 therapy works, and how the body will process DZD9008 when used in combination with
 bevacizumab.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06276283
Non-Device Trial